News & Updates
Filter by Specialty:
Histologic margin status predicts relapse in lentigo maligna melanoma
Histologic margin status shows a robust association with progression for lentigo maligna melanoma, suggest the results of a recent study.
Histologic margin status predicts relapse in lentigo maligna melanoma
26 Oct 2023
Niraparib tied to more toxicities than olaparib in ovarian cancer
Use of niraparib appears to contribute to a higher risk of haematological toxicities as compared with olaparib, suggests a study. The most common haematological adverse event is anaemia.
Niraparib tied to more toxicities than olaparib in ovarian cancer
25 Oct 2023
First-line therapies for advanced NSCLC improve survival, QoL
Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.
First-line therapies for advanced NSCLC improve survival, QoL
16 Oct 2023
Behavioural interventions improve screening colonoscopy uptake
Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.
Behavioural interventions improve screening colonoscopy uptake
16 Oct 2023
Free PSA improves prediction of prostate cancer
Adding percent free prostate-specific antigen (PSA) to total PSA results in better prediction of clinically significant prostate cancer and fatal prostate cancer in men, reports a study.
Free PSA improves prediction of prostate cancer
13 Oct 2023
Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.